Literature DB >> 6244077

Human skin fibroblasts from individuals genetically predisposed to cancer are sensitive to an SV40-induced T antigen display and transformation.

L Kopelovich, S Sirlin.   

Abstract

In the present study we have used a viral probe to determine the genetic susceptibility of fibroblastic cell strains derived from individuals with hereditary adenomatosis of the colon and rectum (ACR), an autosomal dominant trait. This report shows an increased sensitivity of apparently karyologically-normal diploid skin fibroblasts from ACR individuals to an SV40-induced T antigen display and transformation. None of the SV40-transformed cells grew as tumors in athymic mice and they all appeared to have a finite life span. The results suggest that the induction of T antigen positive cells by SV40 may be used as a marker of cancer risk in this cell system.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6244077     DOI: 10.1002/1097-0142(19800315)45:5+<1108::aid-cncr2820451314>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Increased expression of SV40 T antigen and cell division in skin fibroblast cell lines derived from a family at high risk of carcinoma (family G of Warthin).

Authors:  A S Lubiniecki; H T Lynch; W A Blattner; H Guirgis
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

2.  The DNA tumor virus SV 40 induces gene mutations in human cells. Reversion of HPRT deficiency.

Authors:  L Lübbe; M Strauss; S Scherneck; E Geissler
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

3.  APC +/- alters colonic fibroblast proteome in FAP.

Authors:  Bhavinkumar B Patel; Xin-Ming Li; Maketa P Dixon; Elena L Blagoi; Emmanuelle Nicolas; Steven H Seeholzer; David Cheng; Yin A He; Renata A Coudry; Sharon D Howard; Dawn M Riddle; Harry C Cooper; Bruce M Boman; Peggy Conrad; James A Crowell; Alfonso Bellacosa; Alfred Knudson; Anthony T Yeung; Levy Kopelovich
Journal:  Oncotarget       Date:  2011-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.